

IN THE CLAIMS

1. (currently amended): The method of ~~improving FMF control, in humans, treating Familian Mediterranean Fever (FMF) in a patient suffering from FMF, which includes comprises orally administering, on an average daily basis, for at least 5 months, between 5 and 15 milligrams of LTRA leukotriene receptor antagonist (LTRA) selected from the group consisting of 4-5-cyclopentyloxy-carbonylamino-1-methyl-indol-3-ylmethyl-3-methoxy-N-o-tonylsulfanylbenzamide and montelukant sodium to [a] said patient suffering from FMF, for treatment only of FMF and continuing said administration as long as the FMF symptoms continue.~~
2. (canceled)
3. (currently amended): The method of claim [2] 1 wherein said LTRA is administrated orally in tablet form.
4. (original): The method of claim 1 wherein about 10 milligrams of said LTRA is administered, on a daily basis.
5. (currently amended): The method of claim 1 wherein said ~~humans are patient is~~ between 9 and 72 years old.
6. (currently amended): The method of claim [2] 1 wherein said LTRA consists of ZAFIRLUCAST tablets.
7. (currently amended): The method of claim [2] 1 wherein said LTRA consists of SINGULAIR tablets.